The State Medical Insurance Administration ("SMIA") has recently issued the Announcement on Issuing the Range of Drugs under the Specialized Negotiation for the Inclusion of Anticancer Drugs into the Coverage of Medical Insurance in 2018 (the "Announcement").
The Announcement states that, as required by the State Council, the SMIA has made faster progress in the specialized negotiation for the inclusion of anticancer drugs into the coverage of medical insurance, by arranging for around 70 experts from 20 provinces nationwide to select, through expert reviews and voting, 18 drug species from 12 enterprises as targets under the coming special negotiation for adding such anticancer drugs to the coverage of medical insurance, with the written consent of these enterprises to have the negotiation. Along with the Announcement, the Range of Drugs under the Specialized Negotiation for the Inclusion of Anticancer Drugs to the Coverage of Medical Insurance in 2018 was released, covering the Axitinib (mainly used to treat the renal cell carcinoma), Nilotinib (mainly used to treat chronic myelogenous leukemia) and Regorafenib (mainly used to treat hepatocellular carcinoma and colorectal cancer), among others.